CSPC Pharmaceutical Group (HK:1093) has released an update.
CSPC Pharmaceutical Group Limited has renewed its Master Purchase Agreement with CHL, extending their previous arrangement for purchasing products beyond the original estimate and expiration, now set to last from 1 July 2024 to 30 June 2027. This new agreement, which involves transactions with a connected person, adheres to the Listing Rules and is subject to regular reporting and review obligations. The terms of the renewed agreement promise competitive market pricing and commercial fairness for CSPC.
For further insights into HK:1093 stock, check out TipRanks’ Stock Analysis page.
